Glyscend’s dynamic barrier approach seeks to provide the benefits of gastric bypass surgery and duodenal exclusion devices to type 2 diabetic, overweight, and/or obese patients without the need for an invasive surgery or procedure.
Mimicking the effect of bariatric surgery with an oral pill
Our uniquely designed drugs, based on a polymer therapeutic platform, are taken orally and can non-invasively mimic the physiology of bariatric surgery.
Leveraging decades of experience in gastroenterology, metabolism, polymer chemistry, and drug development
Glyscend’s team has contributed to over 25 FDA-approved therapeutic products, many being first-in-class, including Byetta®, Bydureon®, Renagel®, and Welchol®.
Latest News
Press Release | September 5, 2023
Glyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer
Press Release | July 27, 2023